Denali Therapeutics Inc. (DNLI) Net margin 2018–2023
Denali Therapeutics Inc. (DNLI) net profit margin by fiscal year — reported net income divided by reported revenue.
-43.9%FY2023 · since FY2018: -28.1% → -43.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -43.9% | +266.3 pp |
| FY2022 | -310.3% | +286.9 pp |
| FY2021 | -597.2% | -618.4 pp |
| FY2020 | 21.2% | +772.0 pp |
| FY2019 | -750.8% | -722.7 pp |
| FY2018 | -28.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating marginDNLI Operating cash flowDNLI Free cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →